title: Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature.
abstract: Primary indolent leptomeningeal lymphoma is a rare entity, and corresponds in most cases to mucosa-associated lymphoid tissue (MALT) type lymphoma. We are reporting a case of a 75 years old woman, who presented with a 2-year history of behavioral disorder, progressive memory loss and aphasia. Neuroimaging showed a mass infiltrating the frontal circumvolutions and the roof of the orbit. The biopsy revealed an infiltration of the dura by an indolent lymphoma, characteristic of a MALT-type lymphoma. Complete staging work-up did not show any evidence of systemic involvement. A treatment with systemic methotrexate, combined with intrathecal chemotherapy and followed by radiotherapy (30,6 Gy) of the primary site, was conducted. The 3-year follow-up confirms the persistent remission, the patient remaining well and free of symptoms. The review of the literature highlights the importance to recognize the indolent PLML as a distinct clinical entity, which exhibits a rather good prognosis following a relatively non-toxic therapy.
authors.affiliation: Department of Oncology and Haematology, Pluridisciplinary Center for Oncology, CHUV, BH-06, 1011 Lausanne, Switzerland.
authors.forename: Anne-Claude
authors.initials: AC
authors.lastname: George
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
authors.forename: Robert
authors.initials: R
authors.lastname: Janzer
authors.forename: Siverio
authors.initials: S
authors.lastname: Agassis
authors.forename: Reto
authors.initials: R
authors.lastname: Meuli
authors.forename: Audrey S
authors.initials: AS
authors.lastname: Baur
authors.forename: Valérie
authors.initials: V
authors.lastname: Frossard
authors.forename: Serge
authors.initials: S
authors.lastname: Leyvraz
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ketterer
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D004388:Dura Mater; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D018442:Lymphoma, B-Cell, Marginal Zone / Q000134:cerebrospinal fluid / Q000473:pathology* / Q000628:therapy; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000473:pathology* / Q000628:therapy; D008727:Methotrexate / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D006854:Hydrocortisone; D008727:Methotrexate